Latigo reports Q3 2026 results, names new CEO, adds opioid arm to Phase 3 trial
Latigo said its Phase 3 bunionectomy and safety trials of onzotrigine remain on track for 2027 topline data as Todd Smith succeeds Nima Farzan as CEO.
SEC filing (2)
3 stories
Latigo said its Phase 3 bunionectomy and safety trials of onzotrigine remain on track for 2027 topline data as Todd Smith succeeds Nima Farzan as CEO.
SEC filing (2)
Collegium Pharmaceutical agreed to pay Grünenthal GmbH $17 million to end a patent suit and terminate their license tied to the Nucynta products.
SEC filing